4-bromo-N'-butylbenzohydrazide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-N'-butylbenzohydrazide
• 英文别名: UF010
• 化学式: C₁₁H₁₅BrN₂O
• 分子量: 271.157
• InChiKey: BVQCFCYPFJOOAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  正丁醛 、 对溴苯甲酰肼 在 对甲苯磺酸 、 甲醇 、 sodium cyanoborohydride 作用下， 以 甲醇 、 1,4-二氧六环 为溶剂， 反应 15.0h， 以58%的产率得到4-bromo-N'-butylbenzohydrazide
  参考文献：
  名称：

  [EN] HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT
  [FR] COMPOSÉS INHIBITEURS DE HDAC ET MÉTHODES DE TRAITEMENT

  摘要：

  这种瞬时发明描述了具有治疗活性的含有肼基的化合物，以及治疗诸如癌症、肿瘤和细胞增殖相关疾病或影响细胞分化、去分化或转分化的方法。

  公开号：

  WO2015153516A1

文献信息

• HDAC inhibitor compounds and methods of treatment
  申请人：University of Florida Research Foundation, Inc.

  公开号：US10807944B2

  公开（公告）日：2020-10-20

  The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.

  本发明描述了具有治疗活性的含酰肼化合物，以及治疗癌症、肿瘤和细胞增殖相关疾病等疾病或影响细胞分化、去分化或转分化的方法。
• Regulators of the endoplasmic reticulum proteostasis network
  申请人：The Scripps Research Institute

  公开号：US11135186B2

  公开（公告）日：2021-10-05

  The invention provides compounds for activating the activating transcription factor 6 (ATF6) arm of the unfolded protein response (UPR), or activating the transcriptional targets of ATF6, in the endoplasmic reticulum of a cell, the compounds being of any of formulas (I) through (IX) as described herein. The compounds can be used for treatment of conditions involving gain-of-toxic-function and loss-of-function folding disorders including lysosomal storage diseases, antitrypsin-associated emphysema and similar diseases. These molecules are also expected to have disease-ameliorating effects in Alzheimer's disease and diabetes.

  本发明提供了用于激活细胞内质网中未折叠蛋白反应（UPR）的激活转录因子6（ATF6）臂或激活ATF6的转录靶标的化合物，所述化合物为本文所述的式(I)至式(IX)中的任何一种。这些化合物可用于治疗涉及毒性功能增益和功能丧失折叠障碍的疾病，包括溶酶体贮积疾病、抗胰蛋白酶相关性肺气肿和类似疾病。这些分子还有望对阿尔茨海默病和糖尿病产生疾病改善作用。
• HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT
  申请人：University of Florida Research Foundation, Inc.

  公开号：US20170174619A1

  公开（公告）日：2017-06-22

  The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
• [EN] REGULATORS OF THE ENDOPLASMIC RETICULUM PROTEOSTASIS NETWORK<br/>[FR] RÉGULATEURS DU RÉSEAU DU RÉTICULUM ENDOPLASMIQUE IMPLIQUÉ DANS LA PROTÉOSTASIE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2017117430A1

  公开（公告）日：2017-07-06

  The invention provides compounds for activating the activating transcription factor 6 (ATF6) arm of the unfolded protein response (UPR), or activating the transcriptional targets of ATF6, in the endoplasmic reticulum of a cell, the compounds being of any of formulas (I) through (IX) as described herein. The compounds can be used for treatment of conditions involving gain-of-toxic-function and loss-of-function folding disorders including lysosomal storage diseases, antitrypsin-associated emphysema and similar diseases. These molecules are also expected to have disease-ameliorating effects in Alzheimer's disease and diabetes.
• [EN] HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT<br/>[FR] COMPOSÉS INHIBITEURS DE HDAC ET MÉTHODES DE TRAITEMENT
  申请人：UNIV FLORIDA

  公开号：WO2015153516A1

  公开（公告）日：2015-10-08

  The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.

  这种瞬时发明描述了具有治疗活性的含有肼基的化合物，以及治疗诸如癌症、肿瘤和细胞增殖相关疾病或影响细胞分化、去分化或转分化的方法。